Autres langues Revance Therapeutics, Inc.

Actions

RVNC

US7613301099

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 29/04/2024			Varia. 5j.	Varia. 1 janv.
3,69 ^USD	+8,53 %		+1,37 %	-58,02 %

26/04	AbbVie relève ses prévisions de bénéfices annuels en raison des fortes ventes de Skyrizi	RE
12/04	Revance Therapeutics, Inc. présentera de nouvelles données sur DAXXIFY lors de la réunion annuelle de l'American Academy of Neurology 2024	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

AbbVie raises annual profit forecast on strong Skyrizi sales	26/04
Revance to Present New DAXXIFY Data at the American Academy of Neurology 2024 Annual Meeting	15/04
Northern District Of California Grants Motion To Dismiss Putative Class Action Against Biotech Company And Executives	15/04
Revance to Present New DAXXIFY® Data at the American Academy of Neurology 2024 Annual Meeting	12/04
Revance Therapeutics, Inc. to Present New DAXXIFY Data at the American Academy of Neurology 2024 Annual Meeting	12/04
Revance Reports Inducement Grants under Nasdaq Listing Rule 5635(4)	28/03
Revance Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	27/03
North American Morning Briefing: Stock Futures Fall With Investor Focus on Inflation Data	11/03
Court Finds Access To Botox Trade Secrets And Similarity Of Competitor Product Supported Inference Of Trade Secrets Misappropriation	07/03
Revance Therapeutics Prices $100 Million Public Offering	04/03
Revance Announces Pricing of $100.0 Million Public Offering of Common Stock	04/03
Revance Announces Proposed Public Offering of Common Stock	04/03
Earnings Flash (RVNC) REVANCE THERAPEUTICS Posts Q4 Revenue $69.8M	28/02
Revance Reports Fourth Quarter and Full Year 2023 Financial Results, Provides Corporate Update	28/02
Revance Therapeutics, Inc. Provides Revenue Guidance for the Year 2024	28/02
Revance Therapeutics, Inc. Announces Executive Changes	28/02
Revance Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	28/02
Revance to Release Fourth Quarter and Full Year 2023 Financial Results on Wednesday February 28, 2024	21/02
Revance to Participate in Upcoming Investor Conferences	21/02
Revance Therapeutics Gets Permanent J-Code for Daxxify	02/02

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Revance Therapeutics, Inc.

Actions

RVNC

US7613301099

Autres langues

Filtres